18 results were returned
Bird & Bird provide practical insights and expert commentary on some key areas of Life Sciences Law in Australia in the 2020 edition of the Chambers Global Practice Guide on Life Sciences. In particular, we examine ...
The Australian Pharmaceutical Benefits Scheme (PBS) provides for and regulates government subsidies for the supply of certain medicines. A requirement to receive subsidised medicine under the PBS is that the medicine ...
Australia has long lagged behind the USA and UK in its use of generic pharmaceuticals – only around 58% of medicines dispensed in Australia are the generic versus up to 80% in the USA and UK.
The Therapeutic Goods Administration (TGA) announced in mid-2020 that it is conducting a post market review of face masks included in the Australian Register of Therapeutic Goods (ARTG). The announcement came after an ...
On 16 August 2018, the Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Bill 2018 (Bill) passed through both Houses of Parliament and will shortly come into force upon ...
In response to the COVID-19 pandemic, the Australian Federal Minister for Health has exercised his power under section 41GS of the Therapeutic Goods Act 1989 (Cth) (the Act) to exempt certain medical devices from the ...
The Therapeutic Goods Administration (TGA) has been monitoring and taking action against individuals and companies capitalising on the current pandemic to market and sell products that claim to prevent or cure COVID-19.
The Australian Government is currently inviting consumers and industry participants to provide feedback on key provisions of the proposed Information Standard for manufacturers of complementary medicines.
Our Australian competition and IP team have recently contributed a chapter to the Fifth Edition of The Intellectual Property and Antitrust Review.